Repligen (NASDAQ:RGEN) Upgraded at StockNews.com

StockNews.com upgraded shares of Repligen (NASDAQ:RGEN) from a sell rating to a hold rating in a report released on Friday.

Several other equities analysts also recently commented on the company. Canaccord Genuity Group began coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Wolfe Research began coverage on Repligen in a report on Thursday, November 14th. They set a “peer perform” rating on the stock. Canaccord Genuity Group began coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $185.20.

Repligen Trading Up 4.8 %

NASDAQ:RGEN opened at $149.90 on Friday. The stock’s 50 day moving average price is $144.96 and its 200 day moving average price is $142.34. Repligen has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a market capitalization of $8.40 billion, a P/E ratio of -405.12, a P/E/G ratio of 4.64 and a beta of 0.97. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same quarter in the prior year, the company posted $0.23 earnings per share. The firm’s revenue was up 9.7% on a year-over-year basis. On average, research analysts forecast that Repligen will post 1.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Andra AP fonden bought a new position in Repligen in the second quarter worth $25,000. International Assets Investment Management LLC bought a new position in Repligen in the second quarter worth $33,000. UMB Bank n.a. lifted its position in Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares during the period. Blue Trust Inc. lifted its position in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares during the period. Finally, Resources Management Corp CT ADV bought a new position in Repligen in the third quarter worth $37,000. 97.64% of the stock is owned by institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.